Stablepharma partners with the University of Strathclyde to advance their COVID mRNA vaccine thermo-stabilisation technology

Stablepharma has partnered with the University of Strathclyde to advance their COVID mRNA vaccine thermo-stabilisation technology following positive recent COVID mRNA stability data

Bath, UK, 14 July 2021: A British breakthrough invention could form a crucial part in the urgent quest to combat Covid-19 and future virus pandemics. StablevaX™ allows vaccines to be transported and stored for years in a syringe without refrigeration, a unique capability.

Özgür Tuncer, CEO & Executive Director of Stablepharma Ltd, is delighted to announce that Stablepharma has entered into a partnership with the University of Strathclyde in order to advance their COVID mRNA programme, which follows impressive thermo-stability data generated recently.

‘This partnership is excellent news for Stablepharma in the progression of our COVID mRNA vaccine programme’, said Özgür Tuncer. ‘To work with Professor Yvonne Perrie and her team at the University of Strathclyde, which is one of the world’s leading institutions in lipid nano-particle (LNP) and mRNA science, is a great step towards thermo-stabilising COVID vaccines which require refrigeration of up to -80°C'.

‘We have received very encouraging in-vitro data on our COVID mRNA programme, from an independent laboratory in Spain who conducted quantitative PCR tests’, said Dr Arcadio Garcia de Castro, Head of Research & Development at Stablepharma, ‘showing that the whole genome SARS-CoV2-RNA, with both the S and E gene being preserved at +25 °C and +45 °C for 60 days without degradation by our novel StablevaX™ Technology’.

In light of the ongoing COVID-19 pandemic, the challenge of equitable and efficient vaccine delivery has never appeared starker. ‘Our science team have produced a possible breakthrough by thermally stabilising these notoriously unstable genes, working with the University of Strathclyde is a fantastic opportunity for us to quickly progress to the next step to hopefully produce a fridge free solution for the current mRNA Covid vaccines’, added Nick Child, VP & Co Founder of Stablepharma Ltd.

The data demonstrates that the StablevaX™ technology can thermo-stabilise naked COVID mRNA at 45 °C for 2 months and now, Stablepharma and University of Strathclyde will move forward with thermo-stabilising the LNP encapsulated COVID mRNA. ‘This is a particularly important step in our progress as it will model the COVID mRNA vaccine so that it can be transported and stored at room temperature, without the need for refrigeration (‘cold chain’)’. ‘This has the potential to transform vaccine delivery pipelines and dramatically improve vaccine access globally which is at the core of our vision’, said Dr Bruce Roser, Chairman & Founder of Stablepharma.

Currently, the ‘cold chain’ is a significant barrier in front of transporting and storing COVID mRNA vaccines, particularly in countries with unreliable infrastructures, such as India and Brazil. The WHO estimate that up to 50% of all vaccines manufactured currently lose their efficacy before they can be delivered, often as a result of ‘cold-chain’ failures.

Stablepharma is also partnering with the European manufacturer BB-NCIPD Ltd (Bul Bio) in order to create the world’s first fridge-free Tetanus-diphtheria (Td) vaccine. The company have been receiving very encouraging results with Tetadif which will be announced shortly.

Available for comment, contribution and collaboration are:

  • Özgür Tuncer, CEO & Executive Director          otuncer@stablepharma.com
  • Dr. Bruce Roser, Chairman & Founder              bruce.roser@stablepharma.com
  • Nick Child, VP & Co-Founder                                nchild@stablepharma.com

About Stablepharma

Stablepharma Ltd is an innovative biotech company developing a range of next generation thermostable vaccine products. Stablepharma was founded with a simple purpose; to use its novel technology to dramatically improve health outcomes for those adults & children most at risk of death and disability caused by vaccine preventable diseases. www.stablepharma.com.

StablevaX™ is a novel thermo-stabilisation technology and reformulation platform with strong in-vitro and in-vivo animal potency data that aims to eliminate the cold chain.